Schnell Oliver, Almandoz Jaime, Anderson Lisa, Barnard-Kelly Katharine, Battelino Tadej, Blüher Matthias, Busetto Luca, Catrinou Doina, Ceriello Antonio, Cos Xavier, Danne Thomas, Dayan Colin M, Del Prato Stefano, Fernández-Fernández Beatriz, Fioretto Paola, Forst Thomas, Gavin James R, Giorgino Francesco, Groop Per-Henrik, Harsch Igor A, Heerspink Hiddo J L, Heinemann Lutz, Ibrahim Mahmoud, Jadoul Michel, Jarvis Sarah, Ji Linong, Kanumilli Naresh, Kosiborod Mikhail, Landmesser Ulf, Macieira Sofia, Mankovsky Boris, Marx Nikolaus, Mathieu Chantal, McGowan Barbara, Milenkovic Tatjana, Moser Othmar, Müller-Wieland Dirk, Papanas Nikolaos, Patel Dipesh C, Pfeiffer Andreas F H, Rahelić Dario, Rodbard Helena W, Rydén Lars, Schaeffner Elke, Spearman C Wendy, Stirban Alin, Tacke Frank, Topsever Pinar, Van Gaal Luc, Standl Eberhard
Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany.
Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Cardiovasc Diabetol. 2025 May 2;24(1):187. doi: 10.1186/s12933-025-02700-0.
The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20-21, 2025 ( http://www.cvot.org ).
第十届心血管结局试验（CVOT）峰会：心血管、肾脏和代谢结局大会于2024年12月5日至6日以线上形式举行。今年，关于心血管（CV）和肾脏结局试验的讨论集中在涉及恩格列净（EMPACT-MI）、司美格鲁肽（STEP-HFpEF-DM和FLOW）、替尔泊肽（SURMOUNT-OSA和SUMMIT）以及非奈利酮（FINEARTS-HF）的研究的最新发现上。这些研究在降低射血分数保留的心力衰竭（HFpEF）、慢性肾脏病（CKD）和阻塞性睡眠呼吸暂停（OSA）患者的主要不良心血管事件（MACE）风险以及改善代谢结局方面取得了重大进展。大会还包括关于治疗HFpEF、CKD和肥胖的新型及现有疗法的会议；CKD和代谢功能障碍相关脂肪性肝病（MASLD）的管理指南；器官间相互作用以及心肾代谢（CKM）综合征的发展；糖尿病、肥胖、心血管疾病（CVD）和CKD的精准医学和以患者为中心的管理；1型糖尿病（T1D）的早期检测及延迟其发病的策略；持续葡萄糖监测（CGM）和自动胰岛素给药（AID）；心血管自主神经病变（CAN）与糖尿病心脏；以及初级保健在CKM疾病的早期检测、预防和管理中的作用。环境塑料污染对CVD风险的影响、对肠促胰岛素疗法治疗CKM疾病的疗效和安全性的日益了解，以及基于肠促胰岛素疗法的CKM管理营养策略的最新进展，也是众多内分泌学家、糖尿病学家、心脏病学家、肾脏病学家和初级保健医生感兴趣的话题，他们积极参与了线上讨论。第十一届CVOT峰会将于2025年11月20日至21日以线上形式举行（http://www.cvot.org）。
